GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction

This publication has 12 references indexed in Scilit:

• Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
  New England Journal of Medicine, 2025
• Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
  The Lancet, 2025
• GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes
  American Journal of Physiology-Heart and Circulatory Physiology, 2024
• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
  New England Journal of Medicine, 2023
• Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
  Nature Reviews Cardiology, 2023
• Vascular repair and regeneration in cardiometabolic diseases
  European Heart Journal, 2021
• SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
  Cell Metabolism, 2019
• Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes
  JACC: Basic To Translational Science, 2019
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
  New England Journal of Medicine, 2016
• Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem.
  Proceedings of the National Academy of Sciences, 1982